recommendations on the use of recombinant activated factor vii as an adjunctive treatment for massive bleeding – a european perspective建议使用重组激活因子vii作为辅助治疗大量出血u2014u2014欧洲的角度.pdfVIP

Available online /content/10/4/R120 Vol 10 No 4 Open Access Research Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding – a European perspective 1 2 3 4 5 Jean-Louis Vincent , Rolf Rossaint , Bruno Riou , Yves Ozier , David Zideman and Donat R Spahn6 1Department of Intensive Care, Erasme Hospital, Free University of Brussels, Route de Lennik 808, 1070 Brussels, Belgium 2Department of Anaesthesiology of the University Hospital, RWTH, Pauwelsstrasse 30, 52074 Aachen, Germany 3Department of Emergency Medicine and Surgery and Department of Anesthesiology and Critical Care, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Université Pierre et Marie Curie, 47–83 Boulevard de lHôpital, 75651 Paris, France 4Service dAnesthésie-Réanimation Chirurgicale, Hôpital Cochin, Assistance publique-Hôpitaux de Paris, Faculté de Medecine, Paris-V, Université Rene-Descartes, 27 Rue du faubourg Saint-Jacques, 75679 Paris, France 5European Resuscitation Council, ERC Secretariat, Universiteitsplein 1, 2610 Antwerp, Belgium 6Department of Anaesthesiology, University Hospital Lausanne, Rue du Bugnon 46, 1011 Lausanne, Switzerland Corresponding author: Jean-Louis Vincent, jlvincent@ulb.ac.be Received: 10 Jun 2006 Accepted: 18 Aug 2006 Published: 18 Aug 2006 Critical Care 2006, 10:R120 (doi:10.1186/cc5026) This article is online at: /content/10/4/R120 © 2006 Vincent et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (/licenses/by/2.0), which permits unrestricted use, distributio